TD Cowen lowered the firm’s price target on Ultragenyx (RARE) to $75 from $86 and keeps a Buy rating on the shares. The firm said Crysvita Q3 revenues beat, Dojolvi in line, and total revenues were light. FY25 guidance and FY27 profitability reaffirmed.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RARE: